SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5

Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on February 4–5, 2026, with its presentation on Wednesday, February 4, 2026 at 12:00 p.m. ET.

The webcast will be available via the company’s investor site. Management will provide updates on operational progress, strategic priorities, its silicon nitride biomaterial platform, recent regulatory milestones, and opportunities in orthopedic, spine, and patient-specific applications.

News Market Reaction

-2.41%

1 alert

-2.41% News Effect

On the day this news was published, SINT declined 2.41%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Registered shares: 1,741,539 shares Common warrant shares: 1,649,147 shares Placement agent warrant shares: 92,392 shares +5 more

8 metrics

Registered shares 1,741,539 shares Resale registration on Form S-3

Common warrant shares 1,649,147 shares Included in S-3 resale registration

Placement agent warrant shares 92,392 shares Included in S-3 resale registration

Potential proceeds $8.3 million If warrants in S-3 are exercised for cash

Common warrant exercise price $4.79 Warrants covered by S-3 resale registration

Placement warrant price 1 $4.3844 Placement agent warrants in S-3

Placement warrant price 2 $4.3125 Placement agent warrants in S-3

Share price pre-news $3.32 Prior close before Jan 29, 2026 conference announcement

Market Reality Check

Price: $3.21 Vol: Volume 49,295 vs 20-day a...

normal vol

$3.21 Last Close

Volume Volume 49,295 vs 20-day average 37,579 (relative volume 1.31) ahead of the conference update. normal

Technical Price $3.32 trades slightly below the 200-day MA $3.39 before the event-focused news.

Peers on Argus

SINT fell 3.21% while peers showed mixed moves: some modestly higher (e.g., INBS...

1 Down

SINT fell 3.21% while peers showed mixed moves: some modestly higher (e.g., INBS), others lower (e.g., XAIR, CODX, TNON). Only one peer (AIMD) appeared in momentum scans, moving down, suggesting stock-specific trading rather than a broad sector move.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	Investor conference	Positive	+4.5%	Announcement of participation in Sidoti virtual investor conference with webcast access.
Dec 01	Supply agreement	Positive	-21.2%	Supply deal with Evonik for SiN/PEEK compound for AI-assisted 3D-printed implants.
Nov 13	Earnings & update	Positive	-10.8%	Q3 2025 update highlighting FDA clearance, first revenues, capital raised, and cost savings.
Nov 03	Product launch	Positive	+4.7%	Launch of OsseoSculpt biologic complementing cleared SINAPTIC Foot & Ankle system.
Oct 20	FDA clearance	Positive	-15.4%	FDA 510(k) clearance for SINAPTIC Foot & Ankle Osteotomy Wedge System enabling U.S. entry.

Pattern Detected

Recent history shows several positive operational or regulatory updates with mixed to negative next-day price reactions, indicating a tendency toward selling or muted responses even on upbeat news.

Recent Company History

Over the past few months, SINTX announced multiple milestones, including FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System, launch of the OsseoSculpt™ biologic, and a supply agreement for its SiN/PEEK compound. It also regularly participates in investor conferences, such as Sidoti’s event on Dec 10–11, 2025. Today’s Noble conference announcement continues this pattern of outreach and platform-building communications following operational restructuring.

Regulatory & Risk Context

Active S-3 Shelf · $8.3 million

Shelf Active

Active S-3 Shelf Registration 2025-10-23

$8.3 million registered capacity

An effective S-3 resale registration dated Oct 23, 2025 covers up to 1,741,539 shares held by selling stockholders. The company is not selling shares in this prospectus and would receive up to $8.3 million only if related warrants, with exercise prices around $4.79 and $4.38–$4.31, are exercised for cash.

Market Pulse Summary

This announcement highlights SINTX’s participation in an investor conference following operational r...

Analysis

This announcement highlights SINTX’s participation in an investor conference following operational restructuring and a focus on silicon nitride medical technologies. In recent months, the company reported FDA 510(k) clearance, new product launches, and a supply agreement, while also filing an S-3 resale registration for up to 1,741,539 shares. Investors tracking this story may watch for execution against these milestones and how conference outreach supports awareness of its biomaterial platform.

Key Terms

silicon nitride, biomaterial

2 terms

silicon nitride medical

"its expanding silicon nitride biomaterial platform, recent regulatory milestones"

A very hard, lightweight ceramic material made from silicon and nitrogen that resists heat, wear and corrosion. Think of it as industrial-grade pottery that can take extreme conditions where metals or plastics would fail. For investors, its use in high-performance bearings, engine parts, electronics and medical implants can signal exposure to premium, durable products, specialized manufacturing margins and markets with long-term replacement cycles.

biomaterial medical

"its expanding silicon nitride biomaterial platform, recent regulatory milestones"

A biomaterial is any natural or engineered substance designed to interact with living tissue for medical purposes, such as implants, drug delivery systems, or scaffolds for tissue growth. Think of it as the material 'body' of a medical product—like the frame of a device or the sponge that helps tissue repair—which determines safety, performance, regulatory approval chances, and lifespan. Investors watch biomaterials because their biocompatibility, durability, and manufacturing costs directly affect product success, market size, and risk.

AI-generated analysis. Not financial advice.

SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026.

The Company’s participation comes at an important stage in its evolution, following a period of operational restructuring, enhanced financial discipline, and a renewed strategic focus on its core medical-technology platforms. With a more streamlined cost structure, greater visibility into its balance-sheet, and several strategic initiatives underway, SINTX believes the Noble Conference provides a constructive forum to engage with institutional investors seeking differentiated medtech opportunities.

Noble Capital Markets’ Emerging Growth Virtual Equity Conference

• Dates: February 4–5, 2026
• Presentation Date & Time: Wednesday, February 4, 2026, at 12:00 p.m. ET
• Webcast: https://investors.sintx.com/news-events/events-presentations
  
  

During the conference, SINTX management will provide an update on the Company’s operational progress and strategic priorities, including its expanding silicon nitride biomaterial platform, recent regulatory milestones, and opportunities for value creation in orthopedic, spine, and patient-specific applications.

Noble’s Emerging Growth Conference is widely followed by institutional investors, family offices, and research analysts focused on fundamentally driven, under-followed growth companies, and SINTX looks forward to participating in one-on-one meetings and investor discussions throughout the event.

To schedule a one-on-one meeting with SINTX Technologies’ management team, please contact KCSA Strategic Communications at Sintx@kcsa.com.

To be added to the SINTX Technologies email distribution list, please email Sintx@kcsa.com with “SINT” in the subject line.

About SINTX Technologies, Inc.

Based in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is a pioneer in advanced ceramics specializing in silicon nitride-based materials for medical and other high-value applications. SINTX’s biomaterials have been implanted in humans since 2008, and the company continues to expand its portfolio of next-generation orthopedic, spine, and patient-specific solutions through strategic innovation and partnerships.

This press release contains forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties, and actual results may differ materially from those described.

SINTX Contacts:
Jack Perkins or Maria Hocut
KCSA Strategic Communications
Sintx@kcsa.com

SINTX Technologies, Inc.
801.839.3502
IR@sintx.com

FAQ

What will SINTX (SINT) present at Noble Capital Markets on February 4, 2026?

SINTX will present an operational and strategic update at the conference on February 4, 2026. According to the company, the presentation will cover its silicon nitride biomaterial platform, recent regulatory milestones, and opportunities in orthopedic, spine, and patient-specific applications.

When and where can investors watch the SINTX (SINT) Noble conference presentation?

Investors can watch the SINTX presentation live on February 4, 2026 at 12:00 p.m. ET via the company webcast. According to the company, the webcast link is available on its investor news and events page for on-demand viewing after the event.

How can investors schedule a one-on-one meeting with SINTX (SINT) management at the conference?

Investors may request one-on-one meetings by contacting KCSA Strategic Communications at Sintx@kcsa.com. According to the company, interested parties should email Sintx@kcsa.com to arrange meetings or to join the SINTX investor email distribution list with “SINT” in the subject line.

What topics will SINTX (SINT) emphasize in its Noble conference update?

SINTX plans to emphasize its operational restructuring, cost discipline, and strategic focus on medical-technology platforms. According to the company, management will highlight the expanding silicon nitride biomaterial platform and recent regulatory progress relevant to orthopedic and spine applications.

Why is SINTX (SINT) participating in Noble’s Emerging Growth Virtual Equity Conference?

SINTX is participating to engage institutional investors and increase visibility for its medtech opportunities. According to the company, the conference offers a forum for one-on-one meetings with institutional investors, family offices, and research analysts focused on emerging growth companies.